BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng T, Chen G, Qiao X, Chen H, Sun L, Ma Q, Li N, Wang J, Dai C, Xu F. NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer. Front Pharmacol 2022;13:823140. [DOI: 10.3389/fphar.2022.823140] [Reference Citation Analysis]
2 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Simoes Eugénio M, Farooq M, Dion S, Devisme C, Raguenes-Nicol C, Piquet-Pellorce C, Samson M, Dimanche-Boitrel MT, Le Seyec J. Hepatocellular Carcinoma Emergence in Diabetic Mice with Non-Alcoholic Steatohepatitis Depends on Diet and Is Delayed in Liver Exhibiting an Active Immune Response. Cancers (Basel) 2020;12:E1491. [PMID: 32521615 DOI: 10.3390/cancers12061491] [Reference Citation Analysis]
4 Hayashi M, Yamada S, Takano N, Okamura Y, Takami H, Inokawa Y, Sonohara F, Tanaka N, Shimizu D, Hattori N, Kanda M, Tanaka C, Nakayama G, Koike M, Kodera Y. Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma. In Vivo 2021;35:1749-60. [PMID: 33910859 DOI: 10.21873/invivo.12434] [Reference Citation Analysis]
5 Tompkins SC, Sheldon RD, Rauckhorst AJ, Noterman MF, Solst SR, Buchanan JL, Mapuskar KA, Pewa AD, Gray LR, Oonthonpan L, Sharma A, Scerbo DA, Dupuy AJ, Spitz DR, Taylor EB. Disrupting Mitochondrial Pyruvate Uptake Directs Glutamine into the TCA Cycle away from Glutathione Synthesis and Impairs Hepatocellular Tumorigenesis. Cell Rep 2019;28:2608-2619.e6. [PMID: 31484072 DOI: 10.1016/j.celrep.2019.07.098] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
6 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 21.5] [Reference Citation Analysis]
7 Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.Front Oncol. 2019;9:762. [PMID: 31456946 DOI: 10.3389/fonc.2019.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
8 Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. Cancer Res 2019;79:4801-7. [PMID: 31292161 DOI: 10.1158/0008-5472.CAN-19-1167] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 19.3] [Reference Citation Analysis]
9 Akkiz H, Taskin E, Karaogullarindan U, Delik A, Kuran S, Kutlu O. The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e25893. [PMID: 34106646 DOI: 10.1097/MD.0000000000025893] [Reference Citation Analysis]
10 Haque E, Teeli AS, Winiarczyk D, Taguchi M, Sakuraba S, Kono H, Leszczyński P, Pierzchała M, Taniguchi H. HNF1A POU Domain Mutations Found in Japanese Liver Cancer Patients Cause Downregulation of HNF4A Promoter Activity with Possible Disruption in Transcription Networks. Genes 2022;13:413. [DOI: 10.3390/genes13030413] [Reference Citation Analysis]
11 Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Jeon JW, Choi N, Lee SH, Sung JH. Three-tissue microphysiological system for studying inflammatory responses in gut-liver Axis. Biomed Microdevices 2020;22:65. [PMID: 32915326 DOI: 10.1007/s10544-020-00519-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Tong C, Wu H, Gu D, Li Y, Fan Y, Zeng J, Ding W. Effect of curcumin on the non-alcoholic steatohepatitis via inhibiting the M1 polarization of macrophages. Hum Exp Toxicol 2021;:9603271211038741. [PMID: 34470535 DOI: 10.1177/09603271211038741] [Reference Citation Analysis]
14 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
15 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
16 Yang WY, Rao PS, Luo YC, Lin HK, Huang SH, Yang JM, Yuh CH. Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish Model. Cancers (Basel) 2019;11:E1899. [PMID: 31795276 DOI: 10.3390/cancers11121899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
17 Feng S, Meng X, Li Z, Chang TS, Wu X, Zhou J, Joshi B, Choi EY, Zhao L, Zhu J, Wang TD. Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma. J Med Chem 2021;64:15639-50. [PMID: 34590489 DOI: 10.1021/acs.jmedchem.1c00697] [Reference Citation Analysis]
18 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
19 Tovoli F, Ferri S, Piscaglia F. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3909-14. [PMID: 32348210 DOI: 10.2174/1381612826666200429093648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Liu G, Cui Z, Gao X, Liu H, Wang L, Gong J, Wang A, Zhang J, Ma Q, Huang Y, Piao G, Yuan H. Corosolic acid ameliorates non-alcoholic steatohepatitis induced by high-fat diet and carbon tetrachloride by regulating TGF-β1/Smad2, NF-κB, and AMPK signaling pathways. Phytother Res 2021. [PMID: 34213784 DOI: 10.1002/ptr.7195] [Reference Citation Analysis]
22 Lai CY, Yeh KY, Lin CY, Hsieh YW, Lai HH, Chen JR, Hsu CC, Her GM. MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling. Cancers (Basel) 2021;13:940. [PMID: 33668153 DOI: 10.3390/cancers13050940] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Kalra S, Bhattacharya S, Rawal P. Hepatocrinology. Med Sci (Basel) 2021;9:39. [PMID: 34205986 DOI: 10.3390/medsci9020039] [Reference Citation Analysis]
24 Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol 2021;6:4. [PMID: 33437892 DOI: 10.21037/tgh-20-125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
25 Peng Y, Zeng Q, Wan L, Ma E, Li H, Yang X, Zhang Y, Huang L, Lin H, Feng J, Xu Y, Li J, Liu M, Liu J, Lin C, Sun Z, Cheng G, Zhang X, Liu J, Li D, Wei M, Mo Y, Mu X, Deng X, Zhang D, Dong S, Huang H, Fang Y, Gao Q, Yang X, Wu F, Zhong H, Wei C. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun 2021;12:7004. [PMID: 34853313 DOI: 10.1038/s41467-021-27309-1] [Reference Citation Analysis]
26 Eguchi Y, Wong G, Lee I, Akhtar O, Lopes R, Sumida Y. Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works. Hepatol Res 2021;51:19-30. [DOI: 10.1111/hepr.13583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Kudo M. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma? Liver Cancer 2021;10:289-95. [PMID: 34414117 DOI: 10.1159/000517841] [Reference Citation Analysis]
28 Léveillé M, Estall JL. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019;9:E233. [PMID: 31623280 DOI: 10.3390/metabo9100233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
29 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
30 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
31 Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci 2019;76:4869-86. [PMID: 31377844 DOI: 10.1007/s00018-019-03255-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
32 Nehmi VA, Murata GM, Moraes RCM, Lima GCA, De Miranda DA, Radloff K, Costa RGF, Jesus JCR, De Freitas JA, Viana NI, Pimenta R, Leite KRM, Otoch JP, Pessoa AFM. A novel supplement with yeast β-glucan, prebiotic, minerals and Silybum marianum synergistically modulates metabolic and inflammatory pathways and improves steatosis in obese mice. J Integr Med 2021:S2095-4964(21)00059-5. [PMID: 34108131 DOI: 10.1016/j.joim.2021.05.002] [Reference Citation Analysis]
33 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
34 Mass Sanchez PB, Krizanac M, Weiskirchen R, Asimakopoulos A. Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights. Int J Mol Sci 2021;22:5284. [PMID: 34067931 DOI: 10.3390/ijms22105284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hu X, Jiao F, Zhang L, Jiang Y. Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway. Front Pharmacol 2021;12:654986. [PMID: 33995073 DOI: 10.3389/fphar.2021.654986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Martínez-Uña M, López-Mancheño Y, Diéguez C, Fernández-Rojo MA, Novelle MG. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int J Mol Sci 2020;21:E9368. [PMID: 33316927 DOI: 10.3390/ijms21249368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Upadhyaya C, Jiao X, Ashton A, Patel K, Kossenkov AV, Pestell RG. The G protein coupled receptor CCR5 in cancer. Adv Cancer Res 2020;145:29-47. [PMID: 32089164 DOI: 10.1016/bs.acr.2019.11.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
38 Ramos-Tovar E, Muriel P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. J Appl Toxicol 2020;40:151-68. [PMID: 31389060 DOI: 10.1002/jat.3880] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
39 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
40 Saeed RA, Maqsood M, Saeed RA, Muzammil HS, Khan MI, Asghar L, Nisa SU, Rabail R, Aadil RM. Plant-based foods and hepatocellular carcinoma: A review on mechanistic understanding. Crit Rev Food Sci Nutr 2022;:1-34. [PMID: 35796706 DOI: 10.1080/10408398.2022.2095974] [Reference Citation Analysis]
41 Steiger K, Gross N, Widholz SA, Rad R, Weichert W, Mogler C. Genetically Engineered Mouse Models of Liver Tumorigenesis Reveal a Wide Histological Spectrum of Neoplastic and Non-Neoplastic Liver Lesions. Cancers (Basel) 2020;12:E2265. [PMID: 32823526 DOI: 10.3390/cancers12082265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. Clin Transl Sci 2020;13:529-38. [PMID: 31981449 DOI: 10.1111/cts.12735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Kurosaki K, Uesawa Y. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. Biomolecules 2021;11:944. [PMID: 34202146 DOI: 10.3390/biom11070944] [Reference Citation Analysis]
44 Udoh US, Rajan PK, Nakafuku Y, Finley R, Sanabria JR. Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma. IJMS 2022;23:7734. [DOI: 10.3390/ijms23147734] [Reference Citation Analysis]
45 Hong T, Ham J, Song J, Song G, Lim W. Brassinin Inhibits Proliferation in Human Liver Cancer Cells via Mitochondrial Dysfunction. Cells 2021;10:332. [PMID: 33562611 DOI: 10.3390/cells10020332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Petriv N, Neubert L, Vatashchuk M, Timrott K, Suo H, Hochnadel I, Huber R, Petzold C, Hrushchenko A, Yatsenko AS, Shcherbata HR, Wedemeyer H, Lichtinghagen R, Falfushynska H, Lushchak V, Manns MP, Bantel H, Semchyshyn H, Yevsa T. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. Oncoimmunology 2021;10:1874159. [PMID: 33628620 DOI: 10.1080/2162402X.2021.1874159] [Reference Citation Analysis]